Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016 – Global Phase 3 study site recruitment is ongoing
Lugano, Switzerland and San Diego, USA, December 5, 2016 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced final results from a Phase 2 clinical study of the investigational drug candidate Pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) who were not eligible for induction chemotherapy, including evidence of prolongation of survival in the overall population and across a number of patient subgroups.
Linkedin